Results 181 to 190 of about 9,572,367 (390)

Alpha- synuclein immunoreactivity in the enteric nervous system of human small intestine [PDF]

open access: yes, 2018
Alpha-synuclein (α-syn) is a 140 amino acid protein, belonging to the synuclein family, expressed in mammalian neurons. Structural alterations of α-syn as well as its overexpression have been related to the onset and the progression of several human ...
Casini, Arianna   +2 more
core  

Characterization of visual cognition in pre-manifest, manifest and reduced penetrance Huntington’s disease

open access: yesScientific Reports
Cognitive and visual impairment are common in Huntington’s Disease (HD) and may precede motor diagnosis. We investigate the early presence of visual cognitive deficits in 181 participants, including HD carriers (40 pre-manifest, 30 early manifest, 27 ...
Rocio Del Pino   +15 more
doaj   +1 more source

Clinical Characteristics of Parkinsonism in HTLV‐1‐Associated Myelopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Human T‐lymphotropic virus type 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the classic neurological manifestation of HTLV‐1 infection; however, this virus has also been associated with other neurological disorders. Concurrent parkinsonism is relatively rare and presents diagnostic challenges.
Mika Dozono   +8 more
wiley   +1 more source

Effect of lithium on acetylcholine esterase activity, and isozyme pattern in developing chick brain [PDF]

open access: yes, 2004
Acetylcholine Esterase is an enzyme, which hydrolyses acetylcholine and is used as a marker for cholinergic neural function. It is known to be involved in synaptogenesis.
Gouri, Ms Anahita   +3 more
core  

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad   +8 more
wiley   +1 more source

Practicality of a patient self-assessment checklist to manage dementia risk factors in GP practices

open access: yesScientific Reports
A screening tool may help determine who in the population is exposed to which dementia risk factor and, in this way, prevent or delay symptoms. With this study, we examined the practically of using a patient self-completion screening checklist for ...
Francisca S. Rodriguez   +6 more
doaj   +1 more source

Antibodies inhibit transmission and aggregation of C9orf72 poly‐GA dipeptide repeat proteins

open access: yesEMBO Molecular Medicine, 2017
Cell‐to‐cell transmission of protein aggregates is an emerging theme in neurodegenerative disease. Here, we analyze the dipeptide repeat (DPR) proteins that form neuronal inclusions in patients with hexanucleotide repeat expansion C9orf72, the most ...
Qihui Zhou   +18 more
doaj   +1 more source

In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock   +8 more
wiley   +1 more source

Zeolite and Neurodegenerative Diseases

open access: yesMolecules
Neurodegenerative diseases (NDs), characterized by progressive degeneration and death of neurons, are strongly related to aging, and the number of people with NDs will continue to rise. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common NDs, and the current treatments offer no cure.
Stefan Panaiotov   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy